Solid Biosciences Inc.
Why Solid Biosciences Stock Nosedived 67.82% Yesterday
On February 7, Solid Biosciences (SLDB) closed at $7.19, 67.82% lower than its previous closing price.
Solid Biosciences and Its Focus on Duchenne Muscular Dystrophy
In the fourth quarter of 2017, Solid Biosciences initiated a Phase 1/2 clinical trial called IGNITE DMD to test SGT-001 in the United States.
BioMarin Pharmaceutical and Its Promising Research Pipeline
Stocks focused on gene therapy have garnered strong investor interest in 2018. In this series, we’ll analyze four of those companies.
Why resTORbio Stock Is Seeing Solid Growth Today
Today, resTORbio (TORC) is trading at $13.36, which represents 48.28% growth from yesterday when it was trading at $9.01.